These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21683613)

  • 1. Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates.
    Aft R; Perez JR; Raje N; Hirsh V; Saad F
    Crit Rev Oncol Hematol; 2012 May; 82(2):233-48. PubMed ID: 21683613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential anticancer properties of bisphosphonates.
    Neville-Webbe HL; Gnant M; Coleman RE
    Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
    Lipton A
    Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates.
    Lipton A
    Expert Opin Pharmacother; 2011 Apr; 12(5):749-62. PubMed ID: 21247359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer properties of zoledronic acid.
    Green J; Lipton A
    Cancer Invest; 2010 Nov; 28(9):944-57. PubMed ID: 20879838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in breast cancer: antitumor effects.
    Aft R
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):292-9. PubMed ID: 21558988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
    Kanakis I; Kousidou OCh; Karamanos NK
    In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
    Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
    Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates in oncology.
    Coleman RE; McCloskey EV
    Bone; 2011 Jul; 49(1):71-6. PubMed ID: 21320652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate actions on cancer.
    Yoneda T; Hashimoto N; Hiraga T
    Calcif Tissue Int; 2003 Oct; 73(4):315-8. PubMed ID: 12874704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
    Coleman RE
    Eur J Cancer; 2009 Jul; 45(11):1909-15. PubMed ID: 19447606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects and anticancer applications of bisphosphonates.
    Morgan G; Lipton A
    Semin Oncol; 2010 Oct; 37 Suppl 2():S30-40. PubMed ID: 21111246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of bisphosphonates: from the laboratory to the clinic.
    Berenson JR
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):233-40. PubMed ID: 21825999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The crossover of bisphosphonates to cancer therapy.
    Sun M; Iqbal J; Singh S; Sun L; Zaidi M
    Ann N Y Acad Sci; 2010 Nov; 1211():107-12. PubMed ID: 21062299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
    Green JR
    Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of bisphosphonates in cancer therapy.
    Lüftner D; Henschke P; Possinger K
    Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
    Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.